GSK Ends Alector Progranulin Pact After Drug Failures; Alector Repays $10.4M Loan
ALEC sits 68% above its 52-week low of $1.09.
Summary
GSK is terminating its collaboration with Alector for progranulin-elevating antibodies, effective January 2, 2027, due to clinical trial failures of latozinemab (Phase 3) and nivisnebart (Phase 2). This follows Alector's Q1 2026 report of a 71.5% revenue decline and prior discontinuation of nivisnebart. Separately, Alector repaid a $10.4 million loan from Hercules Capital, reducing its debt. The loss of the GSK partnership and pipeline assets is a significant negative for Alector's future prospects, despite the balance sheet improvement from the loan repayment.
At the time of this announcement, ALEC was trading at $1.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $203.2M. The 52-week trading range was $1.09 to $3.40. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.